A widely acclaimed debut book, published this year, has won the prestigious Wellcome Trust book prize, announced last month. The book tells the story of a poor southern tobacco farm worker whose cancer cells, taken without her or her family's knowledge, became one of the most important tools in cell biology and medicine.
When Henrietta Lacks was dying from cervical cancer in a Baltimore hospital in 1951, little did she know that she would one day become one of the most important women in medicine. After her death, scientists removed cells from her body and grew them in the laboratory.
Over the following decades, more than 50 million tonnes of her cells were replicated. "This cell line is used all around the world and revolutionised cell biology because they grew so well in culture, said William Earnshaw, principal research fellow at the University of Edinburgh's Centre for Cell Biology. "They yielded a huge amount of information," he said.
While their research value is unquestioned, the tumour cells had created havoc in Henrietta Lacks' body. Skloot recounts the lab technician Mary Kubicek who was present at the autopsy. "The tumours had completely blocked her urethra, leaving doctors unable to pass a catheter into her bladder to empty it. Tumours the size of baseballs had nearly replaced her kidneys, bladder, ovaries and uterus.
And her other organs were so covered in small white tumours it looked as if someone had filled her with pearls."
It was perhaps the ferocity of her cancer that made the cells grow successfully in the laboratory. "Henrietta's cells weren't merely surviving, they were growing with mythological intensity," writes Skloot. "Soon they were being shipped to research institutes around the world, where they enabled scientists to perform experiments that would have been impossible on a living human," she writes.
The story's relevance to black society has also made the book particularly appealing to parts of the US public. Lacks' story has been portrayed as an example of the mistreatment of African-Americans in the pursuit of medical science.
Skloot recounts the infamous Tuskegee syphilis study, in which poor and uneducated black men with the disease were recruited and then allowed to die preventable deaths while doctors lied to them and withheld penicillin so they could research the course of the disease.
Chairing the judging panel of five, former barrister, comedy writer and presenter Clive Anderson said: "This is an engaging account of the life of Henrietta Lacks, who died in Baltimore nearly 60 years ago, and the immortal life of her cancer cells, which continue to replicate in research laboratories around the world to this day."
He said there are several stories to be told: "the changing attitudes and ethics of the medical profession, the economics of healthcare and the successes and slip-ups of modern scientific methods. In addition, the book reveals the human story of Henrietta Lacks' family, who the author got to know in the course of her extensive research."
He thought it a "worthy winner of a prize designed to honour fine writing on a medical theme."
Matterson added: "It has something of everything -a compelling science story, an emotional personal story and intriguing ethical dilemmas -all woven together and written with great style."
This was the second year of the £25,000 Wellcome Trust book prize, which is open to both fiction and non-fiction on the theme of health and medicine. The short list comprised two other works of non-fiction and three novels, each giving an insight into the medical world. 
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Modified vector attack on dengue
Genetically modified mosquitoes are showing promise in reducing the occurrence of a serious disease. Nigel Williams reports.
There is long history of using the release of laboratory-modified insects to reduce the impact of diseases, some with considerable effect, and a novel modification is showing promise in the fight against dengue fever.
Researchers at the Oxford-based company Oxitec announced last month that a small-scale trial using male mosquitoes that had been genetically modified to be dependent on an antibiotic had cut numbers of the insect in the Cayman Islands by 80 per cent in six months.
The modified mosquitoes mate as normal but die quite quickly in the absence of access to tetracycline. Their offspring inherit the trait and perish quickly too.
"By giving them tetracycline in the lab, we can keep them alive and breed large numbers of them, but when we release them into the environment and they mate with wild females, all the offspring inherit a copy of the gene that kills them if they don't get the antidote… so they die," says Luke Alphey, co-founder of Oxitec.
The mosquito is Aedes aegypti, which spreads dengue fever when females bite humans. Dengue fever causes severe flu-like symptoms and can be lethal. The World Health Organisation estimates there are 50 million cases of dengue fever a year, of which 25,000 are fatal. About 2.5 billion people are at risk, mostly in Africa and south-east Asia. There is no vaccine or treatment and experts say new ways of controlling the disease are urgently needed because of a sharp rise in global infection rates over recent years.
Angela Harris of the Mosquito Research and Control Unit in the Cayman Islands said she was encouraged by the trial, conducted between April and October this year. "This kind of technology really has a place for reducing dengue and having an impact on human health," she said.
Alphey said that his company was in talks with officials in several countries about further and larger trials.
